Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377030904> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4377030904 endingPage "D28" @default.
- W4377030904 startingPage "D28" @default.
- W4377030904 abstract "Abstract Background Transthyretin amyloidosis (ATTR) exists in two forms: a genetic form transmitted by autosomal dominant inheritance (ATTRv) and a wild type form (ATTRwt). Clinically, the hereditary form tends to have an early onset in adulthood and it is characterized by a particular tropism for nervous as well as cardiac tissue. In contrast, the wild type form has a later onset with major cardiac involvement and neurological manifestations usually limited to carpal tunnel syndrome. Methods and results In our centre, from January to October 2022, 20 patients older than 75 years received a diagnosis of cardiac ATTR (73% male, 27% female, mean age 83±5). In all patients, blood tests showed a significant and stable increase in the values of troponin Ths (0.070± 0.074 ng/mL) and NT–proBNP (1533±1204 pg/ml), with the absence of a monoclonal component in the blood and urine, and myocardial bisphosphonate scintigraphy positive grade 2/3. All patients showed absence of peripheral neuropathy with the presence of carpal tunnel syndrome in 9 cases. Before starting therapy with Tafamidis all patients underwent genetic testing by amplification of exons 2,3 and 4 of the TTR gene with subsequent sequencing. Unexpectedly, in 3 elderly male patients (15%) the genetic test resulted positive with 3 different mutations of pathogenetic significance (Val50Met; Ile88Leu; Val142Ile). First–degree relatives (10 consanguineous, average age 49±12 years) agreed to be subjected to genetic screening; of these 4 (1 male and 3 females, age 47±8 years) were positive for the corresponding mutation and underwent echocardiogram, MRI and myocardial scintigraphy. All of these tests were normal and they were included in an annual follow–up protocol at the to identify an early manifestation of the disease. Conclusions our experience shows that 15% of patients older than 75 years and diagnosed with cardiac ATTR may be affected by a genetic form. Making genetic diagnosis in this context is particularly important for screening family members: current therapies are in fact much more effective if started early before organ damage can occur." @default.
- W4377030904 created "2023-05-19" @default.
- W4377030904 creator A5007035969 @default.
- W4377030904 creator A5011100408 @default.
- W4377030904 creator A5025404582 @default.
- W4377030904 creator A5026110064 @default.
- W4377030904 creator A5034420265 @default.
- W4377030904 creator A5036847126 @default.
- W4377030904 creator A5078616038 @default.
- W4377030904 creator A5083043856 @default.
- W4377030904 creator A5091974324 @default.
- W4377030904 date "2023-05-01" @default.
- W4377030904 modified "2023-09-26" @default.
- W4377030904 title "C65 TRANSTYRETIN CARDIAC AMYLOIDOSIS IN THE ELDERLY PATIENT: ALWAYS A WILD TYPE?" @default.
- W4377030904 doi "https://doi.org/10.1093/eurheartjsupp/suad111.064" @default.
- W4377030904 hasPublicationYear "2023" @default.
- W4377030904 type Work @default.
- W4377030904 citedByCount "0" @default.
- W4377030904 crossrefType "journal-article" @default.
- W4377030904 hasAuthorship W4377030904A5007035969 @default.
- W4377030904 hasAuthorship W4377030904A5011100408 @default.
- W4377030904 hasAuthorship W4377030904A5025404582 @default.
- W4377030904 hasAuthorship W4377030904A5026110064 @default.
- W4377030904 hasAuthorship W4377030904A5034420265 @default.
- W4377030904 hasAuthorship W4377030904A5036847126 @default.
- W4377030904 hasAuthorship W4377030904A5078616038 @default.
- W4377030904 hasAuthorship W4377030904A5083043856 @default.
- W4377030904 hasAuthorship W4377030904A5091974324 @default.
- W4377030904 hasBestOaLocation W43770309041 @default.
- W4377030904 hasConcept C121157162 @default.
- W4377030904 hasConcept C126322002 @default.
- W4377030904 hasConcept C141071460 @default.
- W4377030904 hasConcept C187212893 @default.
- W4377030904 hasConcept C2779746960 @default.
- W4377030904 hasConcept C2779951007 @default.
- W4377030904 hasConcept C71924100 @default.
- W4377030904 hasConcept C90924648 @default.
- W4377030904 hasConceptScore W4377030904C121157162 @default.
- W4377030904 hasConceptScore W4377030904C126322002 @default.
- W4377030904 hasConceptScore W4377030904C141071460 @default.
- W4377030904 hasConceptScore W4377030904C187212893 @default.
- W4377030904 hasConceptScore W4377030904C2779746960 @default.
- W4377030904 hasConceptScore W4377030904C2779951007 @default.
- W4377030904 hasConceptScore W4377030904C71924100 @default.
- W4377030904 hasConceptScore W4377030904C90924648 @default.
- W4377030904 hasIssue "Supplement_D" @default.
- W4377030904 hasLocation W43770309041 @default.
- W4377030904 hasOpenAccess W4377030904 @default.
- W4377030904 hasPrimaryLocation W43770309041 @default.
- W4377030904 hasRelatedWork W1970686918 @default.
- W4377030904 hasRelatedWork W2115876300 @default.
- W4377030904 hasRelatedWork W2408474331 @default.
- W4377030904 hasRelatedWork W3080461226 @default.
- W4377030904 hasRelatedWork W3140567676 @default.
- W4377030904 hasRelatedWork W3154213578 @default.
- W4377030904 hasRelatedWork W3165694360 @default.
- W4377030904 hasRelatedWork W4246096042 @default.
- W4377030904 hasRelatedWork W4319963634 @default.
- W4377030904 hasRelatedWork W4385683652 @default.
- W4377030904 hasVolume "25" @default.
- W4377030904 isParatext "false" @default.
- W4377030904 isRetracted "false" @default.
- W4377030904 workType "article" @default.